Advertisement
YOU ARE HERE: LAT HomeCollectionsArena Pharmaceuticals Inc
IN THE NEWS

Arena Pharmaceuticals Inc

MORE STORIES ABOUT:
FEATURED ARTICLES
BUSINESS
December 14, 2005 | From Reuters
Arena Pharmaceuticals Inc. said its experimental obesity drug was effective at all three doses in promoting weight loss after three months in a mid-stage clinical trial. Patients taking the highest dose of 20 milligrams a day lost almost 8 pounds, or about 3.6% of total body weight. It is expected that U.S.
ARTICLES BY DATE
BUSINESS
December 14, 2005 | From Reuters
Arena Pharmaceuticals Inc. said its experimental obesity drug was effective at all three doses in promoting weight loss after three months in a mid-stage clinical trial. Patients taking the highest dose of 20 milligrams a day lost almost 8 pounds, or about 3.6% of total body weight. It is expected that U.S.
Advertisement
NEWS
September 14, 2010
The Food and Drug Administration released information Tuesday suggesting it's unimpressed by a weight-loss medication under development by Arena Pharmaceuticals Inc. and casting doubt on the drug's eventual approval. An FDA advisory committee is scheduled to meet Thursday and vote on whether to recommend approval of the drug, lorcaserin. But in documents released Tuesday in advance of the meeting, the FDA noted that studies on lorcaserin showed the average weight loss while taking the drug was not significantly different than the average weight loss among people taking a placebo.
BUSINESS
May 11, 2005 | Denise Gellene, Times Staff Writer
Arena Pharmaceuticals Inc., a small San Diego biotechnology company, plans to announce today that overweight patients lost an average of 2.9 pounds after taking the company's experimental obesity pill for 28 days in a clinical trial. Chief Executive Jack Lief said the loss was comparable to what was seen with Abbott Laboratories' weight-loss drug Meridia in a month. A three-month study of Arena's drug, ADP356, is planned, Lief said.
BUSINESS
August 30, 2001 | From Bloomberg News
Securities firm Thomas Weisel Partners is firing 80 employees, mostly in investment banking, on expectations that the slump in business at the technology-focused securities firm will continue into next year, a company spokesman said Wednesday. San Francisco-based Weisel plans to fire the employees, about 10% of its staff, this week to reduce costs as fees from advising on mergers and arranging initial public offerings dry up, a company spokesman said.
NEWS
September 16, 2010
This is not shaping up to be a good year for people seeking medical help for weight loss. A Food and Drug Administration advisory committee on Thursday voted against recommending approval of the drug lorcaserin. This is the third negative vote on prescription obesity drugs this year by the advisory committee.   The committee voted, 9 to 5, agaianst recommending approval because the risks of the drugs outweighed the potential benefit of modest weight loss. Studies in animals showed the drug was associated with tumors, although an increased cancer risk has not been seen in human clinical trials.
BUSINESS
March 18, 2008 | Toni Clarke, Reuters
Arena Pharmaceuticals Inc. has bet it can develop a drug from the same family as the notorious diet pill combination fen-phen -- and the gamble may be paying off. Arena, with a market value of just $465 million, is convinced it can make its obesity drug work without causing the heart damage associated with fen-phen. And on Monday, San Diego-based Arena said an interim safety review of a trial of the drug, lorcaserin hydrochloride, showed that it caused no heart safety problems after 12 months.
BUSINESS
July 28, 2000 | From Times Wire Services
Five initial public offerings bucked a selling frenzy that swamped the technology-heavy Nasdaq on Thursday, as new fiber-optic and biotech issues lured investors with their growth prospects. The tech and health deals overcame a 3.7% tumble in the Nasdaq composite index as a spate of disappointing earnings shocked the market.
Los Angeles Times Articles
|